Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 896, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.173897
Keywords
Histamine H-1 receptor antagonist; Doxepin; SARS-CoV-2; Angiotensin-converting enzyme 2; Drug repositioning
Categories
Funding
- National Natural Science Foundation of China [81930096, 81903573]
- Postdoctoral Research Foundation of China [2018M643682]
- Natural Science Basic Research Plan in Shaanxi Province of China [2020JQ-089]
Ask authors/readers for more resources
The COVID-19 pandemic caused by SARS-CoV-2 poses a significant threat to global health, and repurposing histamine H1 receptor antagonists for potential antiviral effects against SARS-CoV-2 infection shows promising results, with doxepin identified as a viable drug candidate for clinical trials.
The spread of the corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been intensifying in the past year, posing a huge threat to global health. There is an urgent need for effective drugs and vaccines to fight the COVID-19, but their advent may not be quite fast. Drug repurposing is a feasible strategy in the current situation, which could greatly shorten drug development time and help to response quickly to the novel virus outbreak. It has been reported that histamine H1 receptor antagonists have broad-spectrum antiviral effects. Therefore, in this study, we aim to screen potential drugs among histamine H1 receptor antagonists that may inhibit SARS-CoV-2 infection. Based on the model of angiotensin-converting enzyme 2 (ACE2) overexpressing HEK293T cell membrane chromatography (CMC), five FDA-approved histamine H1 receptor antagonists were found to have bioaffinity to ACE2. Then we determined the interaction between these drugs and ACE2 by frontal analysis and surface plasmon resonance (SPR), which consistently demonstrated that these hits bind to ACE2 at micromolar levels of affinity. Through the pseudovirus assay, we finally identified that doxepin could inhibit SARS-CoV-2 spike pseudovirus from entering the ACE2expressing cell, reducing the infection rate to 25.82%. These preliminary results indicate that the histamine H1 receptor antagonist, doxepin, is a viable drug candidate for clinical trials. Therefore, we hope the work timely provides rational help for developing anti-SARS-CoV-2 drugs to control the rapid spread of SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available